Costes de la tuberculosis en España

factores relacionados

Translated title of the contribution: Tuberculosis Costs in Spain and Related Factors

José Antonio Gullón, José María García-García, Manuel Ángel Villanueva, Fernando Álvarez-Navascues, Teresa Rodrigo, Martí Casals, Luis Anibarro, Marta María García-Clemente, María Ángeles Jiménez, Ana Bustamante, Antón Penas, José Antonio Caminero, Joan Caylà, Tuberculosis Research Integrated Program Working Group (PIITB)

Research output: Contribution to journalArticle

Abstract

Objective To analyze the direct and indirect costs of diagnosis and management of tuberculosis (TB) and associated factors. Patients and methods Prospective study of patients diagnosed with TB between September 2014 and September 2015. We calculated direct (hospital stays, visits, diagnostic tests, and treatment) and indirect (sick leave and loss of productivity, contact tracing, and rehabilitation) costs. The following cost-related variables were compared: age, gender, country of origin, hospital stays, diagnostic testing, sensitivity testing, treatment, resistance, directed observed therapy (DOT), and days of sick leave. Proportions were compared using the chi-squared test and significant variables were included in a logistic regression analysis to calculate odds ratio (OR) and corresponding 95% confidence intervals. Results 319 patients were included with a mean age of 56.72±20.79 years. The average cost was €10,262.62±14,961.66, which increased significantly when associated with hospital admission, polymerase chain reaction, sputum smears and cultures, sensitivity testing, chest computed tomography, pleural biopsy, drug treatment longer than nine months, DOT and sick leave. In the multivariate analysis, hospitalization (OR=96.8; CI 29–472), sensitivity testing (OR=4.34; CI 1.71–12.1), chest CT (OR=2.25; CI 1.08–4.77), DOT (OR=20.76; CI 4.11–148) and sick leave (OR=26.9; CI 8.51–122) showed an independent association with cost. Conclusion Tuberculosis gives rise to significant health spending. In order to reduce these costs, more control of transmission, and fewer hospital admissions would be required.

Original languageSpanish
Pages (from-to)583-589
Number of pages7
JournalArchivos de Bronconeumologia
Volume52
Issue number12
DOIs
StatePublished - Dec 1 2016
Externally publishedYes

Fingerprint

Spain
Sick Leave
Tuberculosis
Odds Ratio
Costs and Cost Analysis
Length of Stay
Thorax
Therapeutics
Contact Tracing
Cost Control
Sputum
Routine Diagnostic Tests
Hospitalization
Rehabilitation
Multivariate Analysis
Logistic Models
Tomography
Regression Analysis
Prospective Studies
Confidence Intervals

Keywords

  • Cost analysis
  • Hospital income
  • Tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Gullón, J. A., García-García, J. M., Villanueva, M. Á., Álvarez-Navascues, F., Rodrigo, T., Casals, M., ... Tuberculosis Research Integrated Program Working Group (PIITB) (2016). Costes de la tuberculosis en España: factores relacionados. Archivos de Bronconeumologia, 52(12), 583-589. https://doi.org/10.1016/j.arbr.2016.05.015

Costes de la tuberculosis en España : factores relacionados. / Gullón, José Antonio; García-García, José María; Villanueva, Manuel Ángel; Álvarez-Navascues, Fernando; Rodrigo, Teresa; Casals, Martí; Anibarro, Luis; García-Clemente, Marta María; Jiménez, María Ángeles; Bustamante, Ana; Penas, Antón; Caminero, José Antonio; Caylà, Joan; Tuberculosis Research Integrated Program Working Group (PIITB).

In: Archivos de Bronconeumologia, Vol. 52, No. 12, 01.12.2016, p. 583-589.

Research output: Contribution to journalArticle

Gullón, JA, García-García, JM, Villanueva, MÁ, Álvarez-Navascues, F, Rodrigo, T, Casals, M, Anibarro, L, García-Clemente, MM, Jiménez, MÁ, Bustamante, A, Penas, A, Caminero, JA, Caylà, J & Tuberculosis Research Integrated Program Working Group (PIITB) 2016, 'Costes de la tuberculosis en España: factores relacionados', Archivos de Bronconeumologia, vol. 52, no. 12, pp. 583-589. https://doi.org/10.1016/j.arbr.2016.05.015
Gullón JA, García-García JM, Villanueva MÁ, Álvarez-Navascues F, Rodrigo T, Casals M et al. Costes de la tuberculosis en España: factores relacionados. Archivos de Bronconeumologia. 2016 Dec 1;52(12):583-589. https://doi.org/10.1016/j.arbr.2016.05.015
Gullón, José Antonio ; García-García, José María ; Villanueva, Manuel Ángel ; Álvarez-Navascues, Fernando ; Rodrigo, Teresa ; Casals, Martí ; Anibarro, Luis ; García-Clemente, Marta María ; Jiménez, María Ángeles ; Bustamante, Ana ; Penas, Antón ; Caminero, José Antonio ; Caylà, Joan ; Tuberculosis Research Integrated Program Working Group (PIITB). / Costes de la tuberculosis en España : factores relacionados. In: Archivos de Bronconeumologia. 2016 ; Vol. 52, No. 12. pp. 583-589.
@article{e6f52eeca013499496119ca862f97276,
title = "Costes de la tuberculosis en Espa{\~n}a: factores relacionados",
abstract = "Objective To analyze the direct and indirect costs of diagnosis and management of tuberculosis (TB) and associated factors. Patients and methods Prospective study of patients diagnosed with TB between September 2014 and September 2015. We calculated direct (hospital stays, visits, diagnostic tests, and treatment) and indirect (sick leave and loss of productivity, contact tracing, and rehabilitation) costs. The following cost-related variables were compared: age, gender, country of origin, hospital stays, diagnostic testing, sensitivity testing, treatment, resistance, directed observed therapy (DOT), and days of sick leave. Proportions were compared using the chi-squared test and significant variables were included in a logistic regression analysis to calculate odds ratio (OR) and corresponding 95{\%} confidence intervals. Results 319 patients were included with a mean age of 56.72±20.79 years. The average cost was €10,262.62±14,961.66, which increased significantly when associated with hospital admission, polymerase chain reaction, sputum smears and cultures, sensitivity testing, chest computed tomography, pleural biopsy, drug treatment longer than nine months, DOT and sick leave. In the multivariate analysis, hospitalization (OR=96.8; CI 29–472), sensitivity testing (OR=4.34; CI 1.71–12.1), chest CT (OR=2.25; CI 1.08–4.77), DOT (OR=20.76; CI 4.11–148) and sick leave (OR=26.9; CI 8.51–122) showed an independent association with cost. Conclusion Tuberculosis gives rise to significant health spending. In order to reduce these costs, more control of transmission, and fewer hospital admissions would be required.",
keywords = "Cost analysis, Hospital income, Tuberculosis",
author = "Gull{\'o}n, {Jos{\'e} Antonio} and Garc{\'i}a-Garc{\'i}a, {Jos{\'e} Mar{\'i}a} and Villanueva, {Manuel {\'A}ngel} and Fernando {\'A}lvarez-Navascues and Teresa Rodrigo and Mart{\'i} Casals and Luis Anibarro and Garc{\'i}a-Clemente, {Marta Mar{\'i}a} and Jim{\'e}nez, {Mar{\'i}a {\'A}ngeles} and Ana Bustamante and Ant{\'o}n Penas and Caminero, {Jos{\'e} Antonio} and Joan Cayl{\`a} and {Tuberculosis Research Integrated Program Working Group (PIITB)}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.arbr.2016.05.015",
language = "Spanish",
volume = "52",
pages = "583--589",
journal = "Archivos de Bronconeumologia",
issn = "0300-2896",
publisher = "Ediciones Doyma, S.L.",
number = "12",

}

TY - JOUR

T1 - Costes de la tuberculosis en España

T2 - factores relacionados

AU - Gullón, José Antonio

AU - García-García, José María

AU - Villanueva, Manuel Ángel

AU - Álvarez-Navascues, Fernando

AU - Rodrigo, Teresa

AU - Casals, Martí

AU - Anibarro, Luis

AU - García-Clemente, Marta María

AU - Jiménez, María Ángeles

AU - Bustamante, Ana

AU - Penas, Antón

AU - Caminero, José Antonio

AU - Caylà, Joan

AU - Tuberculosis Research Integrated Program Working Group (PIITB)

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Objective To analyze the direct and indirect costs of diagnosis and management of tuberculosis (TB) and associated factors. Patients and methods Prospective study of patients diagnosed with TB between September 2014 and September 2015. We calculated direct (hospital stays, visits, diagnostic tests, and treatment) and indirect (sick leave and loss of productivity, contact tracing, and rehabilitation) costs. The following cost-related variables were compared: age, gender, country of origin, hospital stays, diagnostic testing, sensitivity testing, treatment, resistance, directed observed therapy (DOT), and days of sick leave. Proportions were compared using the chi-squared test and significant variables were included in a logistic regression analysis to calculate odds ratio (OR) and corresponding 95% confidence intervals. Results 319 patients were included with a mean age of 56.72±20.79 years. The average cost was €10,262.62±14,961.66, which increased significantly when associated with hospital admission, polymerase chain reaction, sputum smears and cultures, sensitivity testing, chest computed tomography, pleural biopsy, drug treatment longer than nine months, DOT and sick leave. In the multivariate analysis, hospitalization (OR=96.8; CI 29–472), sensitivity testing (OR=4.34; CI 1.71–12.1), chest CT (OR=2.25; CI 1.08–4.77), DOT (OR=20.76; CI 4.11–148) and sick leave (OR=26.9; CI 8.51–122) showed an independent association with cost. Conclusion Tuberculosis gives rise to significant health spending. In order to reduce these costs, more control of transmission, and fewer hospital admissions would be required.

AB - Objective To analyze the direct and indirect costs of diagnosis and management of tuberculosis (TB) and associated factors. Patients and methods Prospective study of patients diagnosed with TB between September 2014 and September 2015. We calculated direct (hospital stays, visits, diagnostic tests, and treatment) and indirect (sick leave and loss of productivity, contact tracing, and rehabilitation) costs. The following cost-related variables were compared: age, gender, country of origin, hospital stays, diagnostic testing, sensitivity testing, treatment, resistance, directed observed therapy (DOT), and days of sick leave. Proportions were compared using the chi-squared test and significant variables were included in a logistic regression analysis to calculate odds ratio (OR) and corresponding 95% confidence intervals. Results 319 patients were included with a mean age of 56.72±20.79 years. The average cost was €10,262.62±14,961.66, which increased significantly when associated with hospital admission, polymerase chain reaction, sputum smears and cultures, sensitivity testing, chest computed tomography, pleural biopsy, drug treatment longer than nine months, DOT and sick leave. In the multivariate analysis, hospitalization (OR=96.8; CI 29–472), sensitivity testing (OR=4.34; CI 1.71–12.1), chest CT (OR=2.25; CI 1.08–4.77), DOT (OR=20.76; CI 4.11–148) and sick leave (OR=26.9; CI 8.51–122) showed an independent association with cost. Conclusion Tuberculosis gives rise to significant health spending. In order to reduce these costs, more control of transmission, and fewer hospital admissions would be required.

KW - Cost analysis

KW - Hospital income

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85027225379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027225379&partnerID=8YFLogxK

U2 - 10.1016/j.arbr.2016.05.015

DO - 10.1016/j.arbr.2016.05.015

M3 - Article

VL - 52

SP - 583

EP - 589

JO - Archivos de Bronconeumologia

JF - Archivos de Bronconeumologia

SN - 0300-2896

IS - 12

ER -